Stroke and antiphospholipid syndrome-antiphospholipid antibodies are a risk factor for an ischemic cerebrovascular event.
Adult
Antibodies, Antiphospholipid
/ blood
Anticoagulants
/ therapeutic use
Antiphospholipid Syndrome
/ drug therapy
Female
Humans
Logistic Models
Lupus Coagulation Inhibitor
/ blood
Male
Middle Aged
Prospective Studies
Recurrence
Risk Factors
Stroke
/ etiology
Venous Thromboembolism
/ prevention & control
beta 2-Glycoprotein I
/ immunology
Antiphospholipid antibody
Risk
Stroke
Treatment
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
21
04
2018
accepted:
27
07
2018
revised:
26
06
2018
pubmed:
9
8
2018
medline:
29
5
2019
entrez:
9
8
2018
Statut:
ppublish
Résumé
Testing for antiphospholipid antibodies could be an important part in determining the cause of a cerebrovascular event (CVE). Currently, it is also unknown whether antiphospholipid antibodies represent a risk factor for the development of a CVE and whether the selected therapy options are efficacious. So, this study aimed at (1) determining the frequency of patients experiencing a CVE and fulfilling the laboratory criterion for an antiphospholipid syndrome (APS), (2) investigating whether the persistent presence of antiphospholipid antibodies represented a risk factor for a CVE, and (3) focusing on the efficacy of the selected treatment strategy in the first year after the CVE. Eighty-nine patients with an acute CVE were prospectively followed for 1 year. At least two sera from each were tested for lupus anticoagulants, anticardiolipin, anti-β2-glycoprotein I, anti-phosphatidylserine/prothrombin and anti-annexin V antibodies. Twenty out of eighty-nine (22%) of CVE patients fulfilled the criteria for APS (17/20 for definitive and 3 for probable APS). There was a significant association between persistently present antiphospholipid antibodies and the CVE (OR, 4.62). No statistically significant difference was found in the CVE recurrence rate between APS-CVE and non-APS-CVE patients being treated mainly with acetyl salicylic acid. Antiphospholipid antibodies represent an independent risk factor for a CVE. In the first year after the CVE, antiplatelet therapy seemed to be sufficient in secondary CVE thromboprophylaxis in most APS patients.
Identifiants
pubmed: 30088114
doi: 10.1007/s10067-018-4247-3
pii: 10.1007/s10067-018-4247-3
doi:
Substances chimiques
Antibodies, Antiphospholipid
0
Anticoagulants
0
Lupus Coagulation Inhibitor
0
beta 2-Glycoprotein I
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
379-384Subventions
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : P3-0314
Références
J Autoimmun. 2000 Sep;15(2):133-8
pubmed: 10968899
Blood. 2003 Mar 1;101(5):1827-32
pubmed: 12393574
N Engl J Med. 2003 Sep 18;349(12):1133-8
pubmed: 13679527
Clin Chem Lab Med. 2004 Feb;42(2):171-4
pubmed: 15061356
Clin Lab. 2004;50(11-12):653-65
pubmed: 15575307
J Thromb Haemost. 2006 Feb;4(2):295-306
pubmed: 16420554
Int J Med Sci. 2009 Dec 05;7(1):15-8
pubmed: 20046230
Lupus. 2011 Feb;20(2):191-205
pubmed: 21303836
Lupus. 2011 Feb;20(2):206-18
pubmed: 21303837
Clin Chem Lab Med. 2011 Jun;49(6):1011-8
pubmed: 21574879
Arthritis Care Res (Hoboken). 2013 Nov;65(11):1869-73
pubmed: 23861221
Clin Dev Immunol. 2013;2013:724592
pubmed: 24187565
Stroke. 2014 Jul;45(7):2160-236
pubmed: 24788967
Ann Rheum Dis. 2015 Nov;74(11):2028-33
pubmed: 24942381
Thromb Res. 2015 Jan;135(1):46-9
pubmed: 25456002
J Stroke Cerebrovasc Dis. 2015 Aug;24(8):e209-11
pubmed: 25979425
Pol Arch Med Wewn. 2015;125(9):672-7
pubmed: 26307097
Lupus. 2017 Feb;26(2):163-169
pubmed: 27432808
Clin Rheumatol. 2017 Feb;36(2):407-412
pubmed: 28000012
Clin Rheumatol. 2017 Mar;36(3):599-608
pubmed: 28130684
Yonsei Med J. 2017 Nov;58(6):1128-1134
pubmed: 29047236
Stroke. 2018 Mar;49(3):e46-e110
pubmed: 29367334
N Engl J Med. 2018 May 24;378(21):2010-2021
pubmed: 29791828
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
Stroke. 1994 Feb;25(2):333-7
pubmed: 8303740
Thromb Haemost. 1995 Oct;74(4):1185-90
pubmed: 8560433
Int Arch Allergy Immunol. 1997 Jan;112(1):19-26
pubmed: 8980460